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The pedunculopontine tegmental nucleus (PPTg) has been proposed as a target for deep brain stimulation (DBS) in parkinsonian
patients, particularly for symptoms such as gait and postural difficulties refractory to dopaminergic treatments. Several patients have
had electrodes implanted aimed at the PPTg, but outcomes have been disappointing, with little evidence that gait and posture are
improved. The PPTg is a heterogeneous structure. Consequently, exact target sites in PPTg, possible DBS mechanisms, and potential
benefits still need systematic investigation in good animal models. We have investigated the role of PPTg in gait, developed a refined
model of parkinsonism including partial loss of the PPTg with bilateral destruction of nigrostriatal dopamine neurons that mimics
humanpathophysiology, and investigated the effect ofDBSat differentPPTg locationsongait andpostureusing awireless device that lets
rats move freely while receiving stimulation. Neither partial nor complete lesions of PPTg caused gait deficits, underlining questions
raised previously about the status of PPTg as a motor control structure. The effect of DBS in the refined and standard model of parkin-
sonism were very different despite minimal behavioral differences in nonstimulation control conditions. Anterior PPTg DBS caused
severe episodes of freezing and worsened gait, whereas specific gait parameters weremildly improved by stimulation of posterior PPTg.
These results emphasize the critical importance of intra-PPTg DBS location and highlight the need to take PPTg degeneration into
considerationwhenmodeling parkinsonian symptoms. They also further implicate a role for PPTg in the pathophysiology of parkinsonism.
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Introduction
The pedunculopontine tegmental nucleus (PPTg) has a role in
parkinsonism: there is cholinergic and noncholinergic cell loss
(Hirsch et al., 1987; Rinne et al., 2008; Pienaar et al., 2013) and
altered activity in remaining neurons (Mitchell et al., 1989;
Orieux et al., 2000; Breit et al., 2001; Aravamuthan et al., 2008).
Since 2005, PPTg deep brain stimulation (DBS) has been used to
address symptoms such as gait, postural disturbances, and freez-
ing of gait (FOG). Despite initial positive reports (Mazzone et al.,
2005; Plaha and Gill, 2005; Stefani et al., 2007), subsequent stud-
ies were disappointing (Ferraye et al., 2010). The hypothesis that
PPTg DBS could correct axial symptoms came from two assump-
tions: (1) dysfunction of basal ganglia (BG) output nuclei has a
pathological effect on PPTg that might be corrected by local low-
frequency stimulation; and (2) PPTg is a locomotor control
structure (Pahapill and Lozano, 2000; Nandi et al., 2002). This
second assumption is based on primate studies that report frank
motor effects of lesions centered on (but including more than)
the PPTg (Kojima et al., 1997; Munro-Davies et al., 1999). How-
ever, other primate studies show that firing PPTg neuron firing
relates more to cognitive functions, not movement (Kobayashi
and Okada, 2007). Studies in cats, rats, and mice are not consis-
tent with PPTg being a motor control center (Inglis et al.,
1994a,b; Alderson et al., 2003; Homs-Ormo et al., 2003; Steiniger
and Kretschmer, 2004; Winn, 2006). Rather, it has a role in learn-
ing and decision making, with subtle deficits in motor control
emerging only as task difficulty increases (Olmstead et al., 1998;
Corrigall et al., 2001; Samson and Chappell, 2001; Alderson et al.,
2004, 2006; Diederich and Koch, 2005; Kobayashi and Okada,
2007; Wilson et al., 2009; Thompson and Felsen, 2013; MacLaren
et al., 2014). Differences in anatomical organization are unlikely
to account for different experimental outcomes: PPTg structure
and connectivity is highly conserved from teleost fish through to
humans (Rye et al., 1987; Brantley and Bass, 1988; Mesulam et al.,
1989; Medina and Reiner, 1994; Marín et al., 1997; Stephenson-
Jones et al., 2011).
The PPTg contains populations of cholinergic, GABAergic,
and glutamatergic neurons, with different distributions and pat-
terns of connections (Ros et al., 2010; Martinez-Gonzalez et al.,
2011); for example, BG output is directed to anterior and sensory
input to posterior parts (Winn, 2008), creating functional differ-
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ences across the PPTg (Alderson et al., 2008). This raises ques-
tions about whether the consequences of PPTg DBS depend on
location and what kinds of effects to expect. Given the variable
nature of PPTg DBS in parkinsonian patients and uncertainty
about functional differentiation within the PPTg, we under-
took experiments in rodent models to define the therapeutic
potential for PPTg DBS. We did this by doing the following:
(1) assessing the effect of both full and partial PPTg lesions on
gait and posture, (2) combining a partial PPTg lesion with
bilateral destruction of substantia nigra part compacta (SNc)
dopamine (DA) neurons to model better the pathology of
parkinsonism; and (3) examining the effects on gait of DBS in
different PPTg locations.
Materials andMethods
Subjects
One hundred eight adult male Lister Hooded rats (Harlan Olac) weigh-
ing 317–396 g were housed singly under a 12 h light/dark cycle and with
food control. Body weight was monitored daily and food adjusted (never
less than 15 g/d per rat) to maintain stable weight; water was available ad
libitum. Experiments were performed in compliance with the United
Kingdom Animals (Scientific Procedures) Act 1986 and European Com-
munities Council Directive of 24/11/86 (86/609/EEC).
Experimental design
At the start of each experiment, rats were trained for 10 –12 d on the
Noldus CatWalk to measure gait and posture. Rats were then tested for
3– 4 d to obtain a presurgical baseline. Experiment 1 examined the role of
the PPTg in the symptomatology of parkinsonism, Experiment 2 tested a
novel model of parkinsonism, and DBS of the anterior PPTg (aPPTg;
Experiment 3) and posterior PPTg ( pPPTg; Experiment 4) was exam-
ined to determine whether there were beneficial effects on gait and pos-
ture. Experimental protocols are shown in Figure 1.
Surgical procedures
All surgical procedures were performed with rats secured in a stereotaxic
frame (David Kopf Instruments) under isoflurane anesthesia (2–3% iso-
flurane and 1.4 L/min O2) and pretreated with an analgesic (Rimadyl;
0.05 ml/rat carprofen, 5% w/v, i.p.; Pfizer). After surgery, animals re-
ceived intraperitoneal injections of Hartmann’s solution (1 ml/h sur-
gery; Baxter Healthcare).
PPTg lesions. Excitotoxic lesions of the PPTg were made following an
established protocol (Wilson et al., 2009). In brief, in two surgical pro-
cedures separated by 1 week, the PPTg was lesioned bilaterally by pres-
sure injection of 180 nl of 0.09 – 0.12 M ibotenic acid for full lesions and
200 nl of 0.06 M ibotenic acid for partial lesions into the aPPTg or pPPTg
at these coordinates [incisor bar elevated to create a horizontal angle of
8°29 between it and the interaural line (IAL) (Whishaw et al., 1977)]: in
Experiments 1 and 2: aPPTg,0.6 mm IAL,2.0 mm midline, and7.0
mm from dura; pPPTg,0.8 mm IAL,1.9 mm midline, and6.5 mm
from dura; in Experiments 3 and 4: aPPTg,0.5 mm IAL,2.0 mm mid-
line, and7.0 mm from dura; pPPTg,0.7 mm IAL,1.9 mm midline,
and6.7 mm from dura. Sham-operated controls underwent identical pro-
cedures but received only vehicle (sterile phosphate buffer).
DA depletion using 6-OHDA. Seven micrograms (free base weight) of
6-OHDA-hydrobromide dissolved in 2l of sterile 0.1% L-ascorbic acid/
0.9% saline shortly before infusion were delivered bilaterally at four sites
in the striata at the following coordinates (incisor bar at 0 mm): (1)1.3
mm anteroposterior (AP; from bregma), 2.6 mm mediolateral (ML;
from the midline at the skull surface),5.0 mm dorsoventral (DV; from
dura); (2)0.4 mm AP,3.0 mm ML,5.0 mm DV; (3)0.4 mm AP,
4.2 mm ML,5.0 mm DV; and (4)1.3 mm AP,4.5 mm ML,5.0
mm DV. Infusions were made (1 l/min) via 30 gauge stainless steel
cannulae connected via polyethylene tubing to 10l syringes mounted in
a Harvard microdrive pump. Cannulae were left in situ for 2 min after
each infusion before retracting them. Control rats received infusions
only of vehicle.
Combined 6-OHDA and PPTg lesions. Rats receiving combination DA
depletion and partial bilateral PPTg lesions underwent three separate
surgeries. During the first two, bilateral partial PPTg lesions were
created; after an additional 7 d recovery, the DA-depleting procedure
was performed.
DBS electrode implantation. For DBS experiments, rats received bilat-
eral electrode implants into either the aPPTg or pPPTg. These proce-
dures were conducted during the same surgery as infusion of 6-OHDA.
After the last infusion of 6-OHDA, the incisor bar was elevated to create
a horizontal angle of 8°29 between it and the IAL. Concentric bipolar
electrodes were lowered into place at the same coordinates used for toxin
infusion. Electrodes were made from Teflon-coated platinum/iridium
(90:10) wire (50 m uncoated diameter, 114 m coated diameter; Sci-
ence Products) threaded through 30 gauge stainless steel cannula (Plas-
tics One) insulated with polyolefin 2:1 heat shrink (total diameter, 300
m  50 m; wire protruding, 500 m; length of bared tip of cannula
and wire, 200 m). Anode and cathode of the electrodes were then con-
nected to a connector head stage that was then secured to the skull with
dental cement (methyl methacrylate-based dental acrylic; Simplex
Rapid) anchored by stainless steel screws (0 – 80  1⁄8 and 0 – 80  3⁄32;
Plastics One).
Intracranial stimulation
Chronic stimulation was performed by attaching and securing a wireless
DBS device to the head stage. The home cages were modified to protect
animals from damaging the device and head cap. DBS devices were pro-
grammed to deliver biphasic constant-current square-wave pulses at a
frequency of 25 Hz and pulse width of either 160 s (DBS1 settings) or
500 s (DBS2 settings). First, the threshold for stimulation-induced be-
havioral side-effects, such as slowing or an arrest of exploratory behavior
up to “freezing” and “staring” or erected whiskers and/or ears, was de-
termined for each rat individually in a stepwise procedure (starting at
30A, increases of 20A). Each stimulation epoch was no longer than
20 s with at least 1 min between epochs. The intensity for chronic
stimulation was set at 20% of the side-effect-inducing intensity and
retested and further adjusted if animals still appeared disturbed by stim-
ulation. Final average stimulation intensities were as follows: in Experi-
ment 3: DBS1, 78 A (range, 56 –120 A); DBS2, 61 A (range, 4072
A); in Experiment 4: DBS1, 107A (range, 72–136A); DBS2, 105A
(range, 72–152A; here, for both settings, the intensity was lower for the
6-OHDA group than for the other groups).
Behavioral testing
CatWalk. Gait testing was conducted on the CatWalk 7.1 (Noldus). The
principal working mechanisms of the CatWalk are explained in the study
by Hamers et al. (2006). In brief, rats traverse a 100 12 0.6 cm glass
walkway, motivated by their home cage being present at the far end for
them to return to after testing. A camera mounted below the runway
captures footfall: the spacing and size of each print is assessed to derive
measures of gait. Before presurgery testing, rats were trained for 10 –12 d
on the CatWalk to ensure an acceptable performance of three consecu-
tive non-interrupted runs. The following parameters were analyzed: (1)
for gait stability: base of support (BOS; distance between the two fore-
paws and two hindpaws), duty cycle (stance duration expressed as a
percentage of the duration of the step cycle), support [percentage of
contact of two diagonal paws (diagonal) or three paws (three) with the
ground of all combinations of numbers of paws]; (2) for velocity: swing
speed; (3) for stride: stride length; and (4) for coordination: print posi-
tion (distance between the position of the hindpaw and the position of
the previously placed forepaw on the ipsilateral side within the same step
cycle).
FOG. During Experiments 3 and 4, rats showed moderate to severe
freezing during testing. Unlike gait hesitation in the middle of a run
(slowing down and coming to a stop) reflecting destination hesitation
according to the classification of Fahn (1995) (see Schaafsma et al., 2003),
which had been observed previously, in the DBS studies, some rats suf-
fered from severe start hesitation. If no run at all (or not the required
three runs per testing session) could be recorded, the performance was
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recorded as such (freezing leading to less than three runs and freezing
leading to complete lack of data for the session).
L-DOPA administration. As part of the DBS experiments, rats received
injections of L-DOPA [12 mg  kg1  ml1 L-3,4-dihydroxyphenyl-
alanine methylester (free base weight) plus 15 mg  kg1  ml1 bensera-
zide hydrochloride (free base weight) in sterile 0.9% saline, i.p.; Fig. 1 C].
Immediately after injection, rats were returned to their home cage and
kept under close observation to classify and quantify changes in behavior.
The severity of L-DOPA-induced dyskinesias was assessed by determin-
ing the time for which rats displayed abnormal involuntary movement
(AIM) using a six-point scale (Creese and Iversen, 1973) and presented in
minutes. Behavior was rated as follows: 1, normal; 2, active with bursts of
sniffing and rearing; 3, continuous sniffing and rearing over the entire
area of the cage; 4, continuous abnormal behavior in one place (e.g., up
and down head movements, crossing and lifting of the forelegs); 5, addi-
tional bursts of licking or gnawing of paws, legs, or sides (including
self-mutilation, which was always intercepted by experimenters provid-
ing alternative substrates for gnawing) and/or gnawing of the cage; and 6,
continuous licking and/or gnawing.
Histological analysis
All rats were given a lethal intraperitoneal injection of 200 mg/ml sodium
pentobarbitone (0.6 – 0.8 ml/rat Euthatal; Merial Animal Health) and
transcardially perfused with 0.1% PBS, followed by fixative (4% parafor-
maldehyde in 0.1 M phosphate buffer; 350 ml). Brains were stored in
20% sucrose solution in 0.1 M PB at 4°C before coronal 30 m sections
were cut on a freezing microtome. Parallel sections (1:6) were immunohis-
tochemically processed (free-floating) for the following: (1) neuron-specific
nuclear protein (NeuN) in the upper brainstem using a mouse-derived
anti-NeuN monoclonal antibody (Merck Millipore); (2) ChAT of the
upper brainstem using goat anti-ChAT polyclonal antibody (Merck Mil-
lipore); and (3) tyrosine hydroxylase (TH) and calbindin-D28k (CB; dou-
ble stain) of the midbrain using mouse-derived monoclonal anti-CB
(Sigma-Aldrich) and mouse-derived monoclonal anti-TH. Vector Lab-
oratories Elite ABC kits providing biotinylated secondary antibody, avi-
din, and biotinylated horseradish peroxidase reagent were used, as well as
3,3-diaminobenzidine tetrahydrochloride (Sigma Fast DAB; Sigma-
Aldrich) for NeuN and CB and slate gray peroxidase substrate
(ImmPACT SG; Vector Laboratories) for visualizing TH-containing
Figure 1. Experimental design. At the start of the experiment, all animals were trained for 10–12 d on the Noldus CatWalk. They were then tested for 3–4 d to obtain a presurgical baseline. In
thePPTg lesionexperiment (A), animals thenunderwent two successive surgeries for bilateral PPTg lesionsor sham lesions. After 7d recovery, theywere retrainedand testedover 7 consecutivedays.
Experiment 2 (B) compared the traditional 6-OHDAmodel of Parkinson’s disease to a refinedmodel consisting of striatal DA depletion plus partial lesions of the PPTg, rats with partial PPTg lesions
only and sham controls. This followed the same experimental design, except that postsurgical testing was performed every other day. In Experiments 3 and 4 (C), both parkinsonianmodels (traditional and
refined) and sham controls with implanted DBS electrodes in the aPPTg or pPPTg underwent a series of different testing conditions after surgery: first, a postsurgical baseline was taken (3 d), and then their
response to L-DOPAwasobservedon2consecutivedays.After awashoutperiodof2d, theywere retestedon theCatWalkbeforeDBSwas switchedon. Stimulationwas chronic and lasted6d, and the ratswere
tested ondays 4–6. After a day of rest from stimulation, DBSwas resumed,maintaining the same frequency but changing the pulsewidth. Testing followed the samepattern as before. After testing onday 6
of stimulation, theDBSwas left on. The following2d, the ratswere testing for their reaction to thecombinationof L-DOPAandDBS.DBSwas thenswitchedoff, and the ratsweregivenadayof restbeforebeing
retested for the last time.
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cells. Sections were mounted onto slides, and sections were stained for
NeuN counterstained with cresyl violet.
For lesion assessment, all sections were assessed using a light micro-
scope (Leica DM LB2) at 1.6magnification. The extent of nonselective
damage caused by ibotenic acid in and around the PPTg was assessed on
the NeuN-stained sections, judged by lack of cell bodies. Lesion outlines
were drawn on rat brain atlas schematics (Paxinos and Watson, 2005).
Lesions were assessed visually and rated semiquantitatively from 0 to 4 [0,
no PPTg lesion; 1, small/partial PPTg lesion (50% of NeuN-stained
neurons remaining); 2, partial to full PPTg lesion [	50% of NeuN-
positive (NeuN) neurons remaining]; 3, fully lesioned PPTg (no neu-
rons stained for NeuN in the PPTg area); and 4, extensive lesion covering
PPTg and surrounding tissue]. Animals with either a lack of PPTg lesion
on at least one side (0; PPTg not hit) or lesions that were so extensive that
they damaged the SN (4 on both sides) were excluded. For full lesions,
histology had to show at least lesion in one hemisphere scoring 4 and the
other side scoring 2. For partial lesions (including combined lesion
groups), a score of 1 was required as the minimum and no more than a
score of 3 on either side. To judge the degree of damage to cholinergic
cells, surviving ChAT neurons within the entire PPTg were counted
and expressed as a percentage of the average total cell count taken from
sham-lesioned animals; in the case of Experiments 3 and 4 (with all rats
bearing electrodes, regardless of lesion condition) brains with track le-
sions from the implanted electrodes, neurons of the nontargeted part of
the PPTg (anterior or posterior, respectively) were counted; the percent-
age reflects half of what was counted in controls. To determine the extent
of DA neuron loss, all TH neurons within the dorsal and ventral tier of
the SNc, SN pars medialis, and SN pars lateralis were counted manually.
The additional CB stain was performed to distinguish DA-containing
neurons of the SN from the VTA (including the parabrachial pigmented
area) neurons. All animals of the 6-OHDA groups of Experiments 2– 4
were included in this analysis (16 with 6-OHDA only; 15 with 6-OHDA
and PPTg lesion). These data also formed the basis for correlating the
relationship between DA neuron and PPTg loss.
Statistical analysis
All statistical analyses were performed using SPSS version 21 (IBM).
Mixed ANOVAs were performed to compare within either postsurgery
testing days or testing conditions and between groups. Significant inter-
actions were explored with univariate ANOVAs and repeated-measures
ANOVAs. Greenhouse–Geisser corrections were used when indicated.
Post hoc analyses were performed with Tukey’s HSD tests. Frequency
counts of FOG were analyzed with  2 tests for association. Statistically
significant effects were accepted with a p value 0.05. Correlations be-
tween the amount of cholinergic neuron loss from the PPTg and motor
parameters on the CatWalk were run using Pearson’s correlation.
Results
Histological analysis
In all experiments, only rats with PPTg lesions as described above
(Fig. 2), a loss of TH immunoreactivity of at least 90%, and cor-
rect electrode placements without excessive damage (Fig. 3) were
included in behavioral analyses. Thirteen rats were excluded be-
cause they did not meet criteria, 25 rats died after ibotenic acid
infusions (there are respiratory difficulties after infusion of the
excitotoxin into the PPTg; Wilson et al. 2009), and three rats did
not meet performance criteria in CatWalk training. The final
group sizes were as follows: in Experiment 1: full PPTg lesion, n

6; sham lesion, n
 4; in Experiment 2: partial PPTg lesion, n
 7;
combined lesion, n
 7; 6-OHDA lesion, n
 7; sham lesion, n

8; in Experiment 3: combined lesion, n
 4; 6-OHDA lesion, n

5; sham lesion, n
 5; in Experiment 4: combined lesion, n
 4;
6-OHDA, n
 4; sham lesion, n
 4.
Cell loss after ibotenic acid infusions
PPTg lesion locations and sizes from all experiments are shown in
Figure 2, with representative sections stained to show NeuN and
ChAT immunohistochemistry. Figure 4 shows counts of cholin-
ergic cells in PPTg. Rats in the full PPTg lesion group showed
a mean loss of 68.80% of ChAT neurons (range of 49.92–
93.10%); the partial PPTg lesion group of Experiment 2 lost
56.08% (range of 33.32–72.65%). Cholinergic cell loss in the
combined lesion group of Experiment 2 reached 73.27% (range
of 56.45–95.65%), in Experiment 3 (pPPTg cell count) reached
55.82% (range of 37.46 – 80.15%), and in Experiment 4 (aPPTg
cell count) reached 50.59% (range of 34.69 – 67.35%).
Effect of DA depletion on cholinergic cell count in the PPTg
DA loss from the SNc was assessed with TH and CB immunohis-
tochemistry; representative lesions are shown in Figure 2G. The
traditional parkinsonian model (6-OHDA group) in all experi-
ments was assessed for possible PPTg cholinergic cell loss caused
by a chronically DA-depleted SNc. Did a lack of functioning tar-
get neurons and altered afferent input from the BG contribute to
PPTg damage? In Experiments 2– 4, cholinergic cell survival was
97.26% (range of 83.83–108.05%), 93.38% (range of 77.76 –
106.22%), and 99.69% (range of 73.90 –122.45%), respectively,
and did not differ from sham controls (p
 0.979, p
 0.758, and
p 
 1.000, respectively). Loss of SNc DA neurons did not affect
PPTg cholinergic neuron number.
Effect of PPTg lesions on DA cell survival in the SNc
(Experiment 2)
To test the hypothesis that lack of afferent stimulation of nigral
DA neurons after PPTg degeneration might contribute to DA cell
loss, DA cell counts were examined in rats bearing partial PPTg
lesions. TH cell count was, on average, 89.88% of sham controls
(range of 68.86 –112.33%). Statistically, there was no difference
between the PPTg lesion group and sham controls (p
 0.230).
Behavior
Effect of PPTg lesions on gait: Experiment 1
Full PPTg lesions did not impair rats’ gait in any parameters
(Table 1, Experiment 1). PPTg-lesioned rats did not differ from
sham-operated animals in gait stability, speed, stride, or coordi-
nation (BOS forepaw, F(1,8) 
 2.224, p 
 0.174; BOS hindpaw,
F(1,8)
 0.144, p
 0.714; duty cycle forepaw, F(1,8)
 4.782, p

0.060; duty cycle hindpaw, F(1,8)
 0.223, p
 0.650; support diago-
nal paw,F(1,8)
0.003,p
0.955, support three paws,F(1,8)
1.870,
p 
 0.209; swing speed forepaw, F(1,8) 
 2.938, p 
 0.125; swing
speed hindpaw, F(1,8) 
 2.745, p 
 0.136; stride length forepaw,
F(1,8)
 3.606, p
 0.094; stride length hindpaw, F(1,8)
 2.233, p

0.173; print position right, F(1,8)
 0.226, p
 0.648; print position
left, F(1,8) 
 4.619, p 
 0.064). Likewise, rats bearing partial PPTg
lesions (Experiment 2) showed no differences from controls.
Gait and posture in a combined DA-depletion and PPTg lesion:
Experiments 2–4
The goal of Experiment 2 was to establish a model in rodents to
reflect better the pathophysiology of parkinsonism: did the addi-
tion of partial PPTg lesions change gait and postural impairments
seen after bilateral DA depletion? Data are presented in Table 1
(Experiment 2).
Cholinergic neuron loss and gait patterning. There was a range
in the extent of cholinergic neuron survival after full PPTg le-
sions. However, there was no consistent correlation between cho-
linergic survival and activity on the CatWalk. The deficit in BOS
for the forelimbs only (not the hindlimbs) correlated with cho-
linergic survival (0.85, p
 0.03), but no other measure of speed
or stride showed significant correlation (with either two-tailed or
one-tailed tests).
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Figure 2. A, Representation of lesion extension along the rostrocaudal axis in rats of each experiment after PPTg ibotenic acid infusion. The position of the selected schematics (adapted from
Paxinos and Watson, 2005) on the rostrocaudal axis is represented as the distance from the IAL; in millimeters). Sections IAL2.88 mm through to IAL1.68 mm were identified as sections
containingaPPTgneurons (identifiedbyPPTg cholinergic neurons in shamsandpartially lesioned rats), and those from IAL1.08mmto IAL0.36mmrepresent sections containingpPPTg. Lesion
damage is represented in colored shading: blue for lesions in rats of PPTg lesion groups and red for lesions in rats of combined lesion groups.B–G, Representative histological photomicrographs of
lesions in the aPPTg andpPPTg of rats bearing full lesions in Experiment 1 (B, NeuN stained; C, ChAT stained) and of rats bearing partial lesions in Experiments 2–4 (D, NeuN stained; E, ChAT stained;
F, ChAT stained sections of sham-lesioned rat). G showsmidbrain sections at the level of the SN in 6-OHDA-lesioned rats and shams; sections are double stained for anti-CB and anti-TH. Scale bars:
B, D, 1 mm; C, E, F, 250m; G, short, 1 mm and long, 500m.
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Gait stability. Changes in gait parameters indicate increased
instability in DA-depleted rats: BOS of forelimbs and hindlimbs
was significantly increased in both parkinsonian groups com-
pared with controls (forelimbs, F(3,25) 
 27.154, p 	 0.001;
hindlimbs, F(3,25) 
 20.219, p 	 0.001; Tukey’s HSD: fore-
limbs, combined lesion group, p	 0.001; 6-OHDA group, p	
0.001; hindlimbs, combined lesion group, p	 0.001; 6-OHDA
group, p	 0.001); there was no significant difference between
Parkinson’s disease models (p 
 0.683). The use of diagonal
two-legged support during the gait cycle decreased in parkin-
sonian rats, compensated for by an increase of three-legged
support (diagonal, F(3,25) 
 7.991, p 
 0.001; three, F(3,25) 

5.536, p 
 0.005).
Speed. Swing speed of forelimbs and hindlimbs of both
6-OHDA and refined models of parkinsonism decreased signifi-
cantly compared with shams (forelimbs, F(3,25) 
 26.540, p 	
0.001; hindlimbs, F(3,25)
 66.856, p	 0.001; Tukey’s HSD tests,
all p values 	 0.001). The two models did not differ from each
other (forelimbs, p
 0.492; hindlimbs, p
 0.719).
Stride. Parkinsonian rats took shorter steps than shams (fore-
limbs, F(3,25) 
 13.7795, p 	 0.001; hindlimbs, F(3,25) 
 11.156,
p	 0.001; Tukey’s HSD: forelimbs, combined lesion group, p

0.021; 6-OHDA group, p 	 0.001; hindlimbs, combined lesion
group, p 
 0.068; 6-OHDA group, p 	 0.001). There was no
significant difference between the lesion groups (forelimbs, p 

0.095; hindlimbs, p
 0.134).
FOG: Experiments 3 and 4
In Experiments 3 and 4, it was often difficult for rats to complete
non-interrupted runs or to complete all three required runs be-
cause of severe FOG (starting hesitation). Instances of FOG are
reported as a percentage of all available testing occasions of each
condition (Fig. 5) and analyzed as frequency counts. In Experi-
ment 3, the combined lesion group was more likely to show freez-
ing in all four conditions (postsurgery baseline, (2)
2 
 13.680,
p
 0.001; DBS1, (2)
2 
 27.756, p	 0.001; DBS2, (2)
2 
 24.333,
p	 0.001; DBS-OFF, (2)
2 
 7.200, p
 0.027). In Experiment 4,
no FOG occurred during DBS-OFF, but, in DBS1, the combined
lesion group was more likely to freeze than the 6-OHDA group
((2)
2 
 8.649, p
 0.013).
The effect of PPTg DBS on gait: Experiments 3 and 4
aPPTg DBS. Gait data collection was impaired in this experiment
because of a high incidence of FOG. Figure 5 shows FOG in this
experiment and the subsequent one involving DBS in the pPPTg.
Analysis of gait measures in the aPPTg DBS rats was made using
Figure 3. Electrode placements. Representative photomicrographs of electrode tracks in aPPTg (A, B) and pPPTg (C, D). Track damage was unavoidable but did not compromise behavior.
NeuN-stained sections (A,C)were taken fromthe combined lesiongroupand showcell loss of thePPTgarea. ChAT-stained sections (B,D) are fromthe6-OHDA lesiongroup showing cholinergic PPTg
neurons. Schematic drawings (adapted fromPaxinos andWatson, 2005) representing implantation sites of electrode tips in Experiment 3 (E) and Experiment 4 (F ). Note that one rat of the combined
lesiongroupof Experiment 4wasnot included in theDBS testingand is thereforenot included in these schematics. Red triangles represent sites of electrode tips in the combined lesiongroups, yellow
squares of sites in the 6-OHDA lesion groups, and gray circles of sites in the sham lesion groups. Scale bars: short, 1 mm and long, 500m.
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the available data. Figure 6 presents the principal measures.
Repeated-measures ANOVAs across testing conditions showed
that, in the combined lesion group, there was no difference be-
tween conditions in any parameter; DBS in the aPPTg had no
effect on these rats’ gait (BOS: forelimbs, F(3,3) 
 3.711, p 

0.155; hindlimbs, F(3,3)
 3.337, p
 0.174; duty cycle: forelimbs,
F(3,3) 
 0.184, p 
 0.901; hindlimbs, F(3,3) 
 2.166, p 
 0.271;
support: diagonal, F(3,3)
 0.498, p
 0.709; three, F(3,3)
 0.294,
p 
 0.829; swing speed: forelimbs, F(3,3) 
 0.682, p 
 0.682;
hindlimbs, F(3,3) 
 1.183, p 
 0.447; stride length: forelimbs,
F(3,3) 
 0.377, p 
 0.778; hindlimbs, F(3,3) 
 1.174, p 
 0.449;
print position right: F(3,3)
 6.667, p
 0.077; print position left 1:
F(3,3)
 1.376, p
 0.400).
In the 6-OHDA group, aPPTg DBS had a significant detri-
mental effect on a number of gait parameters. In many cases,
these only came about in DBS2. BOS of the forelimbs increased
compared with the postsurgical baseline deficit with DBS1 and
DBS2. The stance duration of the forelimbs also increased: the
hindlimbs showed the same trend, but the effect was not signifi-
cant. The same was observed regarding support: support over
diagonal paws decreased, but support over three paws increased
significantly with DBS2. Stride length of the hindlimbs was sig-
nificantly shortened with DBS2 stimulation. DBS2 but not DBS1
stimulation slowed swing speed (BOS forelimbs, F(3,12) 

148.367, p	 0.001; DBS1, p
 0.004; DBS2, p
 0.046; duty cycle:
forelimbs, F(3,12)
 14.322, p	 0.001; hindlimbs, F(3,12)
 6.931,
Figure 4. PPTg ChAT count for each experiment, presented as the percentage of themean count in sham-lesioned rats. Graph shows groupmeans SEMs. *p 0.05, **p 0.005, ***p
0.001, a significant difference between PPTg lesion/combined lesion group and shams. PPTg and combined lesion groups did not differ from each other (Experiment 2, p
 0.095) and neither did
6-OHDA and sham lesion groups (Experiment 2, p
 0.979; Experiment 3, p
 0.758; and Experiment 4, p
 1.000). LHS, left-hand side; RHS, right-hand side; brain, total of both sides.
Table 1. Summary of the effect of full PPTg lesions (Experiment 1) and partial PPTg lesions, 6-OHDA lesions, and combined lesions (Experiment 2) on CatWalk gait
parameters
BOS Duty cycle Support Swing speed Stride length Print position
Front Hind Front Hind Diagonal Three Front Hind Front Hind Right Left
Experiment 1
Full PPTg lesion 12.22 0.44 21.66 0.45 44.69 0.44 47.93 0.66 61.79 1.14 8.30 0.91 1.27 0.02 1.37 0.03 165.41 1.78 160.29 1.74 10.02 1.32 11.99 1.44
Sham lesion 9.52 0.59 21.16 0.40 42.33 0.83 47.12 0.83 61.65 1.19 6.02 0.80 1.40 0.03 1.52 0.03 176.55 2.24 168.86 2.60 8.42 1.72 6.89 1.74
Experiment 2
Partial PPTg lesion 12.91 0.31 24.04 0.51 45.70 0.58 50.14 0.77 65.27 1.08 9.56 1.11 1.19 0.02 1.30 0.02*** 159.07 1.88 155.36 1.88 11.06 0.95 12.03 0.81
Combined lesion 18.43 0.38* 30.80 0.43* 47.70 0.85 52.45 1.10 56.73 1.60 17.90 1.73 0.92 0.03* 1.01 0.02* 141.39 2.87*** 139.57 2.90 6.33 1.04 8.72 0.96
6-OHDA lesion 17.25 0.38* 30.35 0.53* 48.39 1.59 55.69 1.29 47.08 2.25** 21.44 2.21** 0.83 0.03* 0.97 0.03* 125.77 3.10* 125.95 2.57* 6.90 2.15 8.19 1.39
Sham lesion 10.34 0.36 22.06 0.39 43.83 0.72 50.27 0.66 61.66 1.17 9.93 1.10 1.26 0.03 1.42 0.03 160.82 2.06 154.74 1.94 7.67 0.95 8.07 0.89
Groupmeans SEMs. Experiment 1, Therewas no significant difference between groups in any of these parameters. Experiment 2, Therewas no significant difference between the combined lesion group and the 6-OHDA lesion group and
mostly no significant difference between the PPTg lesion group and the sham lesion group. *p	 0.001 versus sham lesion group; **p	 0.005; ***p	 0.05.
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p
 0.018, Greenhouse–Geisser corrected; forelimbs: DBS2, p

0.010; support diagonal, F(3,12)
 18.557, p	 0.001; three, F(3,12)

20.694, p 	 0.001; diagonal: DBS2, p 
 0.039; three: DBS2,
p 
 0.001; stride length hindlimbs: F(3,12) 
 8.039, p 
 0.003;
hindlimbs: DBS2, p
 0.040).
pPPTg DBS. FOG in the pPPTg DBS experiment was less se-
vere in both parkinsonian groups (Fig. 5). The principal gait
measures of performance on the CatWalk are shown in Figure 6.
Stimulation with neither a short (DBS1) nor a long (DBS2) pulse
width had an effect on any of the measured gait parameters in the
combined lesion group. However, the 6-OHDA group benefited
from stimulation of the pPPTg. In most cases, stimulation with
DBS1 showed some improvements, but these did not reach sta-
tistical significance. However, stimulation during the DBS2 con-
dition had a significant beneficial effect. Stance duration of the
hindpaws decreased, support with three paws decreased, and
stride length became longer. In contrast, the swing speed increased
with stimulation with DBS1 but not DBS2 stimulation settings.
Stimulation of the pPPTg had no effect on BOS (duty cycle hindpaw,
F(3,9)
8.380,p
0.006; DBS2,p
0.020; support diagonal,F(3,9)

4.951, p
 0.027; three, F(3,9) 
 7.505, p
 0.008; diagonal: DBS2,
p
 0.061; three: DBS2, p
 0.021; stride length forelimbs, F(3,9)

13.555,p
0.001;hindlimbs,F(3,9)
9.957,p
0.003;forelimbs:DBS2,
p
0.045; hindlimbs: DBS2,p
0.044; swing speed forelimbs,F(3,9)

10.633, p 
 0.003; hindlimbs, F(3,9) 
 16.220, p 
 0.001; forelimbs:
DBS1, p
 0.027).
L-DOPA administration. The effects of L-DOPA in Experi-
ments 3 and 4 are shown in Figure 7. The effect of L-DOPA on gait
could not be assessed because the drug at the dose administered
induced dyskinesia-like AIMs, which made testing on the
CatWalk impossible. At a mean time of 11.8 min (range of 7.0 –
20.8 min) after L-DOPA administration, the parkinsonian rats
showed the first AIM, which then became more severe. Sham-
lesioned controls did not show any signs of these. The rate of
progression differed between groups and testing condition. The
total amount of time the lesioned animals showed AIMs did not
differ between groups (anterior DBS-OFF, F(1,7) 
 3.506, p 

0.103; DBS-ON, F(1,6) 
 3.241, p 
 0.122; posterior DBS-OFF,
F(1,6)
 4.057, p
 0.091; DBS-ON, F(1,5)
 0.086, p
 0.781); it
was the quality of AIMs that changed rather than the duration
(Fig. 7).
Figure 7 shows the time for which rats in the different groups
and conditions were dyskinetic. Both parkinsonian groups
showed AIMs after intraperitoneal L-DOPA injections. Irrespec-
tive of the position of the stimulation electrode, the group with
combined DA depletion and PPTg lesions showed more severe
AIMs than the 6-OHDA group and mostly of a different quality
(Fig. 7A,B; licking and biting rather than stereotyped head and
body movements; for details, see the figure legend).
Focusing on these differences (AIMs scores 4 and 6), the anal-
yses showed an amelioration of the severe AIMs in the combined
lesion group with posterior DBS (Fig. 7D) but not with anterior
DBS (Fig. 7C): pPPTg DBS (ON) caused a shift of the L-DOPA-
induced AIMs. The appearance of continuous licking and biting
was reduced, with AIMs instead taking the form of stereotyped
up and down head movements and crossing and lifting of the
forelegs [aPPTg DBS experiment, no interaction of groupDBS
condition (ON/OFF): score 4, F(1,6) 
 4.591, p
 0.076; score 6,
F(1,6)
 0.005, p
 0.944; no effect of condition: score 4, F(1,6)

0.000, p 
 1.000; score 6, F(1,6) 
 1.212, p 
 0.313; pPPTg DBS
experiment: significant effect of condition: score 4, F(1,5)
 9.791,
p 
 0.026; score 6, significant interaction of group  DBS con-
dition, F(1,5)
 8.504, p
 0.033].
Discussion
Key findings
First, the PPTg is not critical for normal gait: neither partial nor
full PPTg lesions effected stability, speed, stride, or coordination.
Addition of a partial PPTg lesion to a DA-depleting lesion did not
affect gait differently from DA depletion alone. However, com-
pared with controls, rats with additional PPTg lesions had no
deficits in hindlimb stride length or the distribution of support,
unlike those with only DA-depleting lesions. Second, loss of
PPTg neurons did not affect SNc DA neuron number or vice
versa. In parkinsonism, in which mechanisms of toxicity and
progression differ from animal models, different events might
occur, but there is no a priori reason to believe that PPTg loss
damages SNc DA neurons. Third, FOG was not seen in rats with
only 6-OHDA lesions but was marked in rats with a 6-OHDA
lesion plus a partial PPTg lesion, as well as an electrode implanted
in the aPPTg but not the pPPTg. Activation of aPPTg electrodes
exaggerated FOG; neither pPPTg electrodes nor DBS had the
same effect. Fourth, effects on gait depended on the parkinsonian
model and target site. In DA-depleted rats with an intact PPTg,
pPPTg DBS ameliorated gait deficits, but aPPTg DBS made them
worse. However, with partial PPTg damage (as in parkinsonism),
DBS was ineffective. It was not the case that partial PPTg lesion
made DBS altogether ineffective: rats with partial PPTg and DA-
depleting lesions developed stronger L-DOPA-induced AIMs
than DA-depleted rats with an intact PPTg. pPPTg DBS (but not
aPPTg DBS) attenuated these; it was possible to activate surviving
neurons for therapeutic benefit.
Figure5. Frequency count of FOGepisodes that resulted in less than three runsper sessionor
considerable difficulties in CatWalk testing expressed as a percentage of the total number of
testing occasions (sessions rats). In the aPPTg DBS experiment, the combined lesion group
was more likely to show freezing in all four conditions. In the pPPTg DBS experiment, the
combined lesion group was more likely to freeze than the 6-OHDA group after stimulation at
DBS1 settings.
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Clinical position
We used stimulation frequencies relevant to clinical work in hu-
mans (and monkeys). Clinically, lower frequencies are consis-
tently most beneficial: higher frequencies cause impairment
(Nandi et al., 2002; Plaha and Gill, 2005). Our pilot experiments
using 130 Hz produced akinesia or freezing, regardless of how
low the intensity. Initial encouraging clinical results after PPTg
DBS (Mazzone et al., 2005; Plaha and Gill, 2005; Stefani et al.,
2007) were not confirmed (Stefani et al., 2013). Follow-up studies
reported a decline of the transient gait amelioration, and double-
blind trials showed no motor improvements with PPTg DBS
measured by Unified Parkinson’s Disease Rating Scale (UPDRS)
or objective measures of freezing (Ferraye et al., 2010). The initial
focus on gait and posture diverted to cognitive deficits: (1) start–
react and reaction time in attentional tasks (Thevathasan et al.,
2010); (2) working memory, verbal fluency, executive function-
ing, and delayed recall (Alessandro et al., 2010; Ceravolo et al.,
2011); and (3) rapid eye movement sleep (Lim et al., 2009). Were
initial clinical expectations based on a flawed hypothesis? The ma-
jority of PPTg DBS publications refer to the PPTg as the major com-
ponent of the MLR, a notion that derives from stimulation studies of
rostral brainstem in decerebrate cats and rats (Garcia-Rill et al., 1987;
Skinner et al., 1990) and lesion studies in monkeys (Kojima et al.,
1997; Aziz et al., 1998; Munro-Davies et al., 1999). This is not entirely
supported now (Garcia-Rill et al., 2011): the lesion studies are prob-
lematic to interpret (Winn, 2006), and recent primate electrophysi-
ological data emphasize nonmotor PPTg functions (Okada and
Kobayashi, 2013). The literature in mice, rats, and cats is consistent:
loss or inactivation of PPTg effects tasks involving learning and de-
cision making but not movement (Swerdlow and Koob, 1987; Dellu
et al., 1991; Inglis et al., 1994a,b; Olmstead and Franklin, 1994; Keat-
ing and Winn, 2002; Alderson et al., 2003; Homs-Ormo et al., 2003;
Steiniger and Kretschmer, 2004; Taylor et al., 2004; Wilson et al.,
2009). It has been argued that PPTg organization and projections
differ in primates but, although there are differences in the strength
of particular PPTg connections (Alam et al., 2011), the pattern of
connectivity is highly conserved across species (Winn, 2008;
Martinez-Gonzalez et al., 2011). What is interesting is the increasing
clinical focus on cognitive deficits; this aligns with experimental
studies, reinforcing the belief that PPTg function is not simple motor
control and validating the utility of rat models for exploring PPTg
function.
Interpretation and conclusion
The animal literature shows that the PPTg has a role in cognitive
functions and sleep (but is not a master switch for sleep–wake tran-
sitions; Saper et al., 2010; Petrovic et al., 2013). What does this mean
for its contribution to movement disorders? Cholinergic, GABAer-
gic, and glutamatergic neurons in the PPTg are distributed along
different rostrocaudal gradients (Mesulam et al., 1983; Wang and
Morales, 2009). Its anatomical, neurochemical, and electrophysi-
ological heterogeneity explains the functional diversity of the
structure, with lesions in different parts having different ef-
fects (Alderson et al., 2008; Wilson et al., 2009; Ros et al., 2010;
Martinez-Gonzalez et al., 2012). Consequently, the effects of
PPTg DBS will depend on the exact location: of the few cases
reporting benefits from PPTg DBS, the best effects were
achieved with posterior stimulation (Ferraye et al., 2010) or
outside the PPTg (Zrinzo et al., 2007). The pPPTg receives fast
sensory input, responding to its meaning and value. In con-
trast, the aPPTg is the principal site of BG input, which brakes
PPTg by GABA-mediated inhibition. Both parts project to
thalamocortical and corticostriatal systems via the thalamus
and midbrain DA neurons, as well as connecting with struc-
tures below, such as the pontine reticular formation and spinal
cord (Pan and Hyland, 2005; Kobayashi et al., 2007; Maskos,
2008; Mena-Segovia et al., 2008a; Okada et al., 2009; Thomp-
son and Felsen, 2013).
aPPTg DBS in this study worsened gait in the 6-OHDA model
and caused marked FOG in the combined lesion group. FOG as a
gait disturbance is not a pure motor problem, and, as in patients,
FOG here was contextual: it did not appear in the home cage, but,
within the confined space of the CatWalk, animals showed pro-
nounced start hesitation. Two possible explanations for aPPTg DBS-
Figure 6. Key findings of the performance on the CatWalk of all groups in Experiments 3 (A) and 4 (B). Graphs show groupmeans SEMs of selected gait parameters measured before surgery,
after surgery, and during DBS1 and DBS2. *p 0.05, **p 0.005, ***p 0.001, significant difference compared with the postsurgery baseline.
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induced FOG are as follows. (1) It could activate local BG-projecting
GABA neurons (Mena-Segovia et al., 2008a). This is plausible but
does not sit easily with the fact that aPPTg damage itself promoted
FOG. (2) Alternatively, FOG might be a consequence of aPPTg DBS,
exacerbating a problem with automatic or habitual control of behav-
ior, a BG function disrupted in parkinsonism. Replacing the auto-
matic control of action effected by the BG (dorsolateral striatum/
posterior lateral putamen) that is disturbed in parkinsonism with
ventral striatal goal-directed processes would account for slower ex-
ecution of movements and susceptibility to interference from other
goal-directed tasks (Redgrave et al., 2010). Redgrave and colleagues
hypothesize that output from ventral striatal goal-directed systems
has to overcome “noisy” output from stimulus–response habitual
control circuits at points at which the two systems converge, such as
the aPPTg. Therefore, loss of functionality here is disabling in situa-
tions with increased need for goal-directed processes to override
automatic and habitual ones. MacLaren et al. (2014) suggest that
motor impairment in complex motor tasks after PPTg lesions might
be attributable to a lack of integration of sensory information—
including nonphysical attributes such as salience and
value—supporting the hypothesis of integration failure at the level of
the PPTg in more complex motor behavior.
Posterior stimulation improved gait parameters in the 6-OHDA
lesion group. Through thalamic connections, the PPTg influences
cortical activity. Mena-Segovia and colleagues (Mena-Segovia et al.,
2008b; Mena-Segovia and Bolam, 2011) have shown that neuro-
chemically identified PPTg neurons differentially effect cortical os-
cillatory activity. Increased activity is seen in several cortical areas
after PPTg stimulation, including the medial sensorimotor area
(Ballanger, 2009). Underactivity here is important in parkinsonian
motor symptoms (Berardelli et al., 2001), and increased activation is
associated with motor improvement (Brooks and Samuel, 2000).
Furthermore, in the parkinsonian rodent model, the relation be-
tween cortical and PPTg activity was shown to be altered (Aravamu-
than et al., 2008). It is likely that benefits seen here after pPPTg DBS
can be attributed to an influence on cortical structures, which will
help ameliorate deficiencies in corticostriatal activity produced by
DA depletion. However, for clinical application, it needs to be high-
lighted that this effect was absent in the model with PPTg degenera-
tion. This suggests that, for patients with advanced parkinsonism,
PPTg DBS is not a promising option. Most studies of PPTg DBS
(including the early ones reporting most improvement) de-
scribe severe gait deficits and high UPDRS scores. The effect of
symptom severity (and likely linked degree of degeneration)
on PPTg DBS outcome is difficult to compare across studies,
because factors, such as electrode placement, number of elec-
trodes, stimulation parameters, and diagnosis, also contrib-
ute. PPTg DBS is only discussed for patients with pronounced
gait impairment, a condition developed in more advanced
stages when DBS in the PPTg, according the results reported
Figure 7. L-DOPA-induced stereotypies. A, Experiment 3. During DBS-OFF, the combined lesion group displayed very severe AIMs (score 6) for longer than those of other severity levels [effect of
score (F(5,15)
 15.890, p	 0.001), Tukey’s corrected pairwise comparisons (score 1, q
 8.089, p	 0.05; score 3, q
 8.632, p	 0.05]. Univariate ANOVAs comparing both groups directly
revealed that the combined lesion group showed AIMs of themost severe stage (score 6) significantly longer that the 6-OHDA group (F(1,7)
 7.151, p
 0.032), although this relation was inverse
regarding dyskinesia score 4 (F(1,7)
 15.890, p
 0.005).B, Experiment 4. The 6-OHDAgroup displayed less severe stages of dyskinesia for longer than the combined lesion group (score 2, F(1,6)

7.377.p
0.035; score 3, F(1,6)
8.828,p
0.025; score 5, F(1,6)
7.573,p
0.033),whereas the combined lesiongroup showed significantlymore continuous lickingandbiting (F(1,6)
9.220,
p
 0.023). C, D, DBS-ON. The effect of L-DOPA did not change in Experiment 3. There was no interaction of group condition (ON vs OFF), regarding neither score 4 (F(1,6)
 4.591, p
 0.076)
nor score 6 (F(1,6)
 0.005, p
 0.944). However, pPPTgDBS (Experiment 4) caused a shift of the L-DOPA-inducedAIMs in the combined lesion group from continuous licking andbiting to dyskinetic
behavior in the form of up/down head movements and crossing/lifting of the forelegs (score 4) [significant interaction of group condition (ON vs OFF; F(1,5)
 8.504, p
 0.033) on score 6].
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here, is not beneficial. However, because the pPPTg can affect
corticostriatal activity, it might be an appropriate target to
address cognitive domains, as the clinical literature suggests
(Po¨tter-Nerger and Volkmann, 2013). Future studies will have
to address the role of the aPPTg in FOG (could this be ame-
liorated by targeted deactivation of GABA input?) and the
precise effects of pPPTg DBS on corticostriatal function. Us-
ing model systems like this systematically might yet reveal the
PPTg to be a valuable therapeutic target in parkinsonism.
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